PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner

Cancer Research

Volumn 66, Issue 2, 2006, Pages 736-742

  Tang, Yufang ^a,c   Eng, Charis ^a,b,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; AUTOREGULATION; BANNAYAN RILEY RUVALCABA SYNDROME; CELL STRAIN MCF 7; CONTROLLED STUDY; COWDEN SYNDROME; ENZYME ACTIVITY; FAMILIAL CANCER; GEL MOBILITY SHIFT ASSAY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

GENE EXPRESSION REGULATION; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; PROMOTER REGIONS (GENETICS); PTEN PHOSPHOHYDROLASE; SYNDROME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 31544454967     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1557     Document Type: Article

References (18)

1. Eng C, Peacocke M. PTEN and inherited hamartoma-cancer syndromes. Nat Genet 1998;19:223.
2. Marsh DJ, Dahia PL, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997;16:333-4.
3. Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, Eng C. Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 2000;9:765-8.
4. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
5. Li J, Simpson L, Takahashi M, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 1998;58: 5667-72.
6. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7.
7. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002;32:355-7.
8. Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell 2001;8: 317-25.
9. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002;277: 5484-9.
10. Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/ Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003;73: 404-11.
11. Latonen L, Kurki S, Pitkanen K, Laiho M. p53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction. Cell Signal 2003;15:95-102.
12. Freeman DJ, Li AG, Wei G, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003;3:117-30.
13. Wiederschain D, Gu J, Yuan ZM. Evidence for a distinct inhibitory factor in the regulation of p53 functional activity. J Biol Chem 2001;276:27999-8005.
14. Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 1998;18:5690-8.
15. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 1998;95:5246-50.
16. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999;155:1253-60.
17. Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res 2003;63:3585-92.
18. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002;70:829-44.